For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

All materials

Help patients make the most of their appointments

Primary Biliary Cholangitis (PBC) File
10 pages

This resource has been developed in collaboration with patients living with PBC and clinicians in the field to reflect their main concerns when it comes to making the most of medical appointments
This material is intended to be viewed online.

IQV-UK-000153 | January 2025

Help patients make the most of their appointments
Explore more Primary Biliary Cholangitis (PBC) Resources

Explore more Primary Biliary Cholangitis (PBC) Resources

Browse

To access relevant information about Primary Biliary Cholangitis, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

I am a patient

This section provides information to support patients that have been prescribed IQIRVO®▼ (elafibranor).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.